Joel G Turner

Title: Innovations in Cancer Treatment by Joel G Turner

Introduction

Joel G Turner is an accomplished inventor based in Land O Lakes, FL (US). He has made significant contributions to the field of cancer research, particularly in developing methods to overcome drug resistance in multiple myeloma. With a total of 2 patents, his work is paving the way for new therapeutic approaches.

Latest Patents

Turner's latest patents focus on drug targets that aim to overcome de novo drug-resistance in multiple myeloma. One of his notable inventions involves the topoisomerase II alpha (topo IIα), which is exported from the cell nucleus in human myeloma cells through a CRM1-dependent mechanism. This process results in resistance to topo II inhibitors. The unique nuclear export signal (NES) of topo IIα makes it a promising target for small molecule inhibitors. Turner identified small molecules that inhibit the binding of topo IIα to the export receptor CRM1, demonstrating specificity as p53 trafficking remained unaffected. These inhibitors may lead to innovative strategies for circumventing drug resistance in multiple myeloma, potentially providing new treatment protocols for oncogenic diseases.

Career Highlights

Throughout his career, Turner has worked with prestigious institutions such as the H. Lee Moffitt Cancer Center and Research Institute and the University of Florida Research Foundation. His research has focused on enhancing the effectiveness of topo II-directed therapeutics, particularly in treating diseases like multiple myeloma.

Collaborations

Turner has collaborated with notable colleagues, including David A Ostrov and Thomas Cardon Rowe. Their combined expertise has contributed to the advancement of cancer treatment methodologies.

Conclusion

Joel G Turner's innovative work in cancer research exemplifies the potential of targeted therapies in overcoming drug resistance. His contributions are vital in the ongoing fight against multiple myeloma and other oncogenic diseases.